Innovative solutions

Disruptive strategy to elicit protective immunity against Multidrug-resistant (MDR) Gram-negative bacteria

RemAb is developing a pipeline with different indications. Our most advanced program aims to provide immediate protection to patients admitted to Intensive Care Units (ICU) without generating antimicrobial resistance (AMR).
 

Read more

 

ABOUT US

RemAb Therapeutics is a spin‐off of Bellvitge Biomedical Research Institute, based in Barcelona.

 

PROBLEM

Antimicrobial resistance (AMR) is a growing global threat to human health and economic development.

 

.

 

PRODUCT

RA01 is novel drug product and a first line therapy for preventing nosocomial infections at ICUs.

 

 

.

 

 

Grants and Awards

 

 

 

Grant from

Caixa Capital Risk

Obra Social "La Caixa"

CaixaImpulse program

July / 2016

Ref.: CI16-00037

Read more

 

 

 

Grant from

CERCA

Generalitat de Catalunya

Fons de Patents Gínjol Program

GAS-1: 2017 – 3rd edition

GAS: 2016 - 1st edition 

Read more

 

 

 

Grant from

EIT Health

European Commission

HeadStart Program

July / 2018

Ref. 2018-HS-0010

Read more

 

 

Grant from

SME phase-I

European Commission

Horizon 2020

December/ 2018

Ref.: Coming soon

Read more

 

 

 

Grant from

Startup Capital

Generalitat de Catalunya

ACCIO

February/ 2019

Ref.: Coming soon

Read more

 

 

Grant from

Kingdom of Saudi Arabia

Ministry of Education

Integration in International programs of entrepreneurship

February/ 2020

Ref.:  Coming soon

Read more

 

 

Grant from

Caixa Capital Risk

Obra Social "La Caixa"

CaixaImpulseConsolidate program

March/ 2020

Ref.: Coming soon

Read more

 

 

 

Grant from

BIOCAT

Generalitat de Catalunya

Emergency call against COVID-19

April/ 2020

Ref.:  Coming soon

Read more